Filing Flows › Denali Therapeutics (DNLI) › Stock forecast & fair value
Denali Therapeutics (DNLI) stock forecast and price target
Denali Therapeutics (DNLI) trades at $20.07. 16 analysts' median price target is $36.00 (+79%), from $24.00 to $46.00.
Denali Therapeutics' latest quarter
Denali Therapeutics, Q3 2026: revenue $17.8M, operating margin -713.0%, net earnings $70.1M, operating cash flow −$117M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for DNLI stock?
The median of 16 analysts' 12-month targets is $36.00, +79% from $20.07; the range is $24.00 to $46.00. The average rating is strong buy.
Does Denali Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is DNLI stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.